PMID- 32369480
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Effect of short-term prednisone on beta-cell function in subjects with type 2 
      diabetes mellitus and healthy subjects.
PG  - e0231190
LID - 10.1371/journal.pone.0231190 [doi]
LID - e0231190
AB  - OBJECTIVE: For those with type 2 diabetes mellitus (T2DM), impact of short-term 
      high-dose glucocorticoid exposure on beta-cell function is unknown. This study 
      aims to compare the impact on beta-cell function and insulin resistance of 
      prednisone 40 mg between adults with newly diagnosed T2DM and healthy adults. 
      METHODS: Five adults with T2DM and five healthy adults, all between 18-50 years, 
      were enrolled. T2DM diagnosis was less than one year prior, HbA1c<75 mmol/mol 
      (9.0%), with metformin treatment only. Pre- and post-therapy testing included 
      75-g oral glucose tolerance, plasma glucose, C-peptide, and insulin. Intervention 
      therapy was prednisone 40mg daily for 3 days. RESULTS: Upon therapy completion, 
      HOMA-IR did not increase or differ between groups. Percentile difference for 
      HOMA-%B and insulinogenic index in those with T2DM was significantly lower 
      statistically (50.4% and 69.2% respectively) compared to healthy subjects (19% 
      and 32.2%). CONCLUSIONS: Contrary to the assumption that insulin resistance is 
      the main driver of glucocorticoid-induced hyperglycemia, results indicate that 
      decreased beta-cell insulin secretion is the more likely cause in those with 
      T2DM. This is evidenced by significant drops in C-peptide AUC and HOMA-%B and 
      increased glucose AUC in T2DM group only. These results may be caused by 
      increased beta-cell fragility along with reduced recovery ability after 
      glucocorticoid exposure. ClinicalTrials.gov NCT03661684.
FAU - Shah, Monica
AU  - Shah M
AD  - John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of 
      America.
FAU - Adel, May M
AU  - Adel MM
AD  - John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of 
      America.
FAU - Tahsin, Bettina
AU  - Tahsin B
AD  - John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of 
      America.
FAU - Guerra, Yannis
AU  - Guerra Y
AUID- ORCID: 0000-0001-5294-9611
AD  - John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of 
      America.
FAU - Fogelfeld, Leon
AU  - Fogelfeld L
AD  - John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of 
      America.
LA  - eng
SI  - ClinicalTrials.gov/NCT03661684
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200505
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Blood Glucose/analysis
MH  - C-Peptide/blood
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/drug therapy/*physiopathology
MH  - Female
MH  - Humans
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Insulin-Secreting Cells/*drug effects
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Prednisone/*pharmacology
MH  - Young Adult
PMC - PMC7199958
COIS- NO authors have competing interests.
EDAT- 2020/05/06 06:00
MHDA- 2020/07/28 06:00
PMCR- 2020/05/05
CRDT- 2020/05/06 06:00
PHST- 2019/10/31 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/05/05 00:00 [pmc-release]
AID - PONE-D-19-24296 [pii]
AID - 10.1371/journal.pone.0231190 [doi]
PST - epublish
SO  - PLoS One. 2020 May 5;15(5):e0231190. doi: 10.1371/journal.pone.0231190. 
      eCollection 2020.